Data published in Scientific Reports demonstrate that extracts from a bioengineered chewing gum can significantly reduce levels of 3 microbes associated with head and neck squamous cell carcinoma (HNSCC), suggesting a potential low-cost supportive strategy in the management of infection-related cancer risk.¹

The medicated chewing gum displayed substantial reductions in oral human papillomavirus (HPV), Porphyromonas gingivalis, and Fusobacterium nucleatum.¹

Rationale for Targeting Oral Oncogenic Microbes

HNSCC arises from the epithelial lining of the oral cavity and oropharynx and is associated with poor outcomes in advanced stages. Despite advances in oncology, many recently approved therapies have not considerably improved long-term survival or quality of life, emphasizing the need for alternative approaches that address additional biological drivers of disease.¹

HPV-driven carcinogenesis is primarily mediated through viral oncoproteins E6 and E7, which disrupt tumor suppressor pathways and contribute to malignant transformation.² Similarly, oral dysbiosis involving anaerobic bacteria such as P gingivalis and F nucleatum has been linked to tumor-promoting inflammation, immune modulation, and treatment resistance.³

The research evaluated a lablab bean–derived chewing gum containing the antiviral lectin FRIL for its effect on microbial loads in oral samples from patients with HNSCC. The goal was to assess HPV, P gingivalis, and F nucleatum, which have been implicated in tumor progression and poorer clinical outcomes in head and neck cancers.^1-3

Study Design and Key Findings

The data analyzed saliva and oral rinse samples from patients with HNSCC and compared microbial levels following exposure to the investigational chewing gum extract. HPV detection was performed using an ELISA (enzyme-linked immunosorbent assay) targeting the viral L1 surface protein.¹

Following treatment with the bean-derived lectin formulation, HPV levels were reduced by approximately 93% and 80% in saliva and oral rinse samples, respectively.¹ The effect is attributed to FRIL-mediated binding of viral glycoproteins, which promotes aggregation and reduces viral availability for host cell entry.¹

To extend antimicrobial activity, the formulation was also bioengineered with protegrin-1, an antimicrobial peptide active against anaerobic bacteria. Together, the chewing gum extract reduced P gingivalis and F nucleatum to near-undetectable levels, achieving reductions greater than 99% in ex vivo samples. Further, pathogenic anaerobes were significantly reduced, whereas commensal streptococcal species were largely preserved, suggesting a more targeted microbial effect than conventional broad-spectrum approaches.¹

Clinical Context

Oral microbiome disruption is a recognized complication of cancer therapies, particularly radiation, which can reduce beneficial bacterial populations while increasing opportunistic pathogens such as Candida albicans.¹ In comparison, the investigational formulation demonstrated selective suppression of cancer-associated microbes while maintaining a more balanced microbial profile in ex vivo conditions.¹

Data show that microbial burden may play a role not only in cancer progression but also in recurrence and treatment resistance, particularly in patients with recurrent or metastatic disease.^1-3

Clinical Implications

Although these findings are still in the preclinical context, they emphasize an emerging area of interest in oncology supportive care: targeted modulation of the oral microbiome. It introduces chewing gum-based formulations as a potential future class of intraoral biologic delivery systems that may require pharmacist counseling regarding their use, adherence, and integration with existing cancer therapies.

Practitioners can monitor for any potential interactions if such biologics advance into clinical practice, particularly in immunocompromised oncology patients. Awareness of microbial contributions to cancer progression may support interdisciplinary care discussions with oncology teams regarding adjunctive preventive strategies.

REFERENCES

1.Daniell H, Wakade G, Singh R, et al. Ex vivo HNSCC clinical studies using saliva and antiviral or antibacterial chewing gums reveal reduction in carcinogenic microbes. Sci Rep. 2026;16(1):7886. doi:10.1038/s41598-026-39062-w

2.Pan C, Issaeva N, Yarbrough WG. HPV-driven oropharyngeal cancer: current knowledge of molecular biology and mechanisms of carcinogenesis. Cancers Head Neck. 2018;3:12. doi:10.1186/s41199-018-0039-3

3.Song X, Wang J, Gu Z, et al. Porphyromonas gingivalis and Fusobacterium nucleatum synergistically strengthen the effect of promoting oral squamous cell carcinoma progression. Infect Agent Cancer. 2025;20(1):60. doi:10.1186/s13027-025-00689-5